CLINICAL STUDY: HEART TRANSPLANT
Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation
Michael Weis, MD*,
Sinan Pehlivanli, MD ,
Bruno M. Meiser, MD and
Wolfgang von Scheidt, MD
* Stanford University Medical School, Falk Cardiovascular Research Center, Stanford, California, USA
Division of Cardiology, University Hospital Grosshadern, Ludwig-Maximilians University of Munich, Munich, Germany
Division of Cardiovascular Surgery, University Hospital Grosshadern, Ludwig-Maximilians University of Munich, Munich, Germany
Manuscript received January 17, 2001;
revised manuscript received May 4, 2001,
accepted May 21, 2001.
Reprint requests and correspondence: Dr. Michael Weis, Stanford University Medical School, Falk Cardiovascular Research Center, 300 Pasteur Drive, Stanford, California 94305
michaweis{at}yahoo.com
OBJECTIVES
This study was designed to assess the association between 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibition, coronary endothelial function and cytokine activation in heart transplant recipients without angiographically detectable disease.
BACKGROUND
Coronary endothelial dysfunction contributes to cardiac allograft vasculopathy. The vasoprotective effects of statins in heart transplant recipients may include restoration of endothelial function and suppression of allograft inflammatory activity.
METHODS
Heart transplant recipients (one to three years after heart transplant) were divided into three groups based on the total cholesterol levels: group 1 (n = 21), patients with a history of hypercholesterolemia adequately controlled with simvastatin; group 2 (n = 19), patients with hypercholesterolemia not adequately treated with simvastatin; and group 3 (n = 40), patients without hypercholesterolemia. Coronary vasomotor function and intimal thickness as well as coronary sinus and aortic cytokine concentrations (tumor necrosis factor [TNF]- , interleukin [IL]-6 and soluble IL-2 receptor) were investigated. In a prospective one-year follow-up study, changes in coronary endothelial function and cytokine levels were compared between 11 hypercholesterolemic patients treated with simvastatin and 9 controls.
RESULTS
Epicardial and microvascular endothelial functions were better in groups 1 and 3 than they were in group 2 (p < 0.01 and p < 0.05). Transcardiac IL-6 and TNF- gradients were significantly increased in groups 2 and 3 compared with group 1 (IL-6: p < 0.05; TNF-: p < 0.01). Plaque areas were significantly increased in groups 1 and 2 (p < 0.05 vs. group 3), whereas lumen area was increased in group 2 compared with group 1 (p < 0.05), demonstrating adaptive vascular remodeling. In patients treated with simvastatin, coronary endothelial function and cardiac cytokine activity significantly improved during the one-year follow-up.
CONCLUSIONS
Inhibition of allograft inflammatory activity and attenuation of the coronary endothelial dysfunction observed in cardiac transplant recipients during treatment with simvastatin may represent an important mechanism by which HMG-CoA reductase inhibitors protect against the development of cardiac allograft vasculopathy.
|
Abbreviations and Acronyms
| | ACh | = acetylcholine | | CRP | = C-reactive protein | | CFVR | = coronary flow velocity reserve | | HMG-CoA | = 3-hydroxy-3-methylglutaryl coenzyme A | | IL | = interleukin | | IVUS | = intravascular ultrasound | | TNF | = tumor necrosis factor |
|
This article has been cited by other articles:
|
|
|
|
 
S. Takahashi, H. Nakamura, M. Seki, Y. Shiraishi, M. Yamamoto, M. Furuuchi, T. Nakajima, S. Tsujimura, T. Shirahata, M. Nakamura, et al.
Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice
Am J Physiol Lung Cell Mol Physiol,
May 1, 2008;
294(5):
L882 - L890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Schmauss and M. Weis
Cardiac Allograft Vasculopathy: Recent Developments
Circulation,
April 22, 2008;
117(16):
2131 - 2141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. I. Paraskevas
Applications of statins in cardiothoracic surgery: more than just lipid-lowering
Eur. J. Cardiothorac. Surg.,
March 1, 2008;
33(3):
377 - 390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Raichlin, J.-H. Bae, Z. Khalpey, B. S. Edwards, W. K. Kremers, A. L. Clavell, R. J. Rodeheffer, R. P. Frantz, C. Rihal, A. Lerman, et al.
Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation
Circulation,
December 4, 2007;
116(23):
2726 - 2733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Flammer, F. Hermann, I. Sudano, L. Spieker, M. Hermann, K. A. Cooper, M. Serafini, T. F. Luscher, F. Ruschitzka, G. Noll, et al.
Dark Chocolate Improves Coronary Vasomotion and Reduces Platelet Reactivity
Circulation,
November 20, 2007;
116(21):
2376 - 2382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. I. Boger, T. K. Rudolph, R. Maas, E. Schwedhelm, E. Dumbadze, A. Bierend, R. A. Benndorf, and R. H. Boger
Asymmetric Dimethylarginine Determines the Improvement of Endothelium-Dependent Vasodilation by Simvastatin: Effect of Combination With Oral L-Arginine
J. Am. Coll. Cardiol.,
June 12, 2007;
49(23):
2274 - 2282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Petrakopoulou, L. Anthopoulou, M. Muscholl, V. Klauss, W. von Scheidt, P. Uberfuhr, B. M. Meiser, B. Reichart, and M. Weis
Coronary Endothelial Vasomotor Function and Vascular Remodeling in Heart Transplant Recipients Randomized for Tacrolimus or Cyclosporine Immunosuppression
J. Am. Coll. Cardiol.,
April 18, 2006;
47(8):
1622 - 1629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Methe, J.-O. Kim, S. Kofler, M. Nabauer, and M. Weis
Statins Decrease Toll-Like Receptor 4 Expression and Downstream Signaling in Human CD14+ Monocytes
Arterioscler. Thromb. Vasc. Biol.,
July 1, 2005;
25(7):
1439 - 1445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Petrakopoulou, M. Kubrich, S. Pehlivanli, B. Meiser, B. Reichart, W. von Scheidt, and M. Weis
Cytomegalovirus Infection in Heart Transplant Recipients Is Associated With Impaired Endothelial Function
Circulation,
September 14, 2004;
110(11_suppl_1):
II-207 - II-212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hognestad, K. Endresen, R. Wergeland, O. Stokke, O. Geiran, T. Holm, S. Simonsen, J. K. Kjekshus, and A. K. Andreassen
Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients
J. Am. Coll. Cardiol.,
August 6, 2003;
42(3):
477 - 482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Vassalli, A. Gallino, M. Weis, W. von Scheidt, L. Kappenberger, L.K. von Segesser, J.-J. Goy, and on behalf of the Working Group Microcirculation of
Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy
Eur. Heart J.,
July 1, 2003;
24(13):
1180 - 1188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Chello, P Mastroroberto, G Patti, A D'Ambrosio, M C. Morichetti, G Di Sciascio, and E Covino
Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass
Heart,
May 1, 2003;
89(5):
538 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weis and J. P. Cooke
Cardiac Allograft Vasculopathy and Dysregulation of the NO Synthase Pathway
Arterioscler. Thromb. Vasc. Biol.,
April 1, 2003;
23(4):
567 - 575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Mehra, P. A. Uber, K. Vivekananthan, S. Solis, R. L. Scott, M. H. Park, R. V. Milani, and C. J. Lavie
Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival
J. Am. Coll. Cardiol.,
November 6, 2002;
40(9):
1609 - 1614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weis, C. L. Schlichting, E. G. Engleman, and J. P. Cooke
Endothelial Determinants of Dendritic Cell Adhesion and Migration: New Implications for Vascular Diseases
Arterioscler. Thromb. Vasc. Biol.,
November 1, 2002;
22(11):
1817 - 1823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Sposito and M. J. Chapman
Statin Therapy in Acute Coronary Syndromes: Mechanistic Insight Into Clinical Benefit
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2002;
22(10):
1524 - 1534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Palinski and S. Tsimikas
Immunomodulatory Effects of Statins: Mechanisms and Potential Impact on Arteriosclerosis
J. Am. Soc. Nephrol.,
June 1, 2002;
13(6):
1673 - 1681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weis, C. Heeschen, A. J. Glassford, and J. P. Cooke
Statins Have Biphasic Effects on Angiogenesis
Circulation,
February 12, 2002;
105(6):
739 - 745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
